Reduced endocannabinoid immune modulation by a common cannabinoid 2 (CB2) receptor gene polymorphism: possible risk for autoimmune disorders.
Immune system responsiveness results from numerous factors, including endogenous cannabinoid signaling in immunocytes termed the "immunocannabinoid" system. This system can be an important signaling pathway for immune modulation. To assess the immunomodulating role of the cannabinoid 2 (CB2) receptor, we sought polymorphisms in the human gene, identified a common dinucleotide polymorphism, and investigated its effect on endocannabinoid-induced inhibition of T lymphocyte proliferation. The CB2 cDNA 188-189 GG/GG polymorphism predicts the substitution of glutamine at amino acid position 63 by arginine. T lymphocytes from CB2 188-189 GG/GG homozygotes had approximately twofold reduction of endocannabinoid-induced inhibition of proliferation compared with cells from CB2 188-189 AA/AA homozygotes. In GG/GG subjects, the reduced endocannabinoid inhibitory response was highly significant for N-arachidonylglycine and nearly significant for 2-arachidonylglycerol, and a specific CB2 receptor antagonist partially blocked these effects. Also, patients with autoimmune diseases had an increased prevalence of the homozygous GG/GG genotype. Collectively, these results demonstrate reduced endogenous fatty acid amide immunomodulatory responses in individuals with the CB2 188-189 GG/GG genotype and suggest that this CB2 gene variation may be a risk factor for autoimmunity. The results also support the proposition that the CB2 receptor may represent a novel pharmacological target for selective agonists designed to suppress autoreactive immune responses while avoiding CB1 receptor-mediated cannabinoid adverse effects.
Sipe
Jack C
JC
Department of Molecular and Experimental Medicine, The Scripps Research Institute (MEM-215), La Jolla, CA 92037, USA. jcsipe@scripps.edu
Arbour
Nathalie
N
Gerber
Alexandra
A
Beutler
Ernest
E
D019943:Amino Acid Substitution / Q000235:genetics; D001095:Arachidonic Acids / Q000276:immunology / Q000378:metabolism / Q000494:pharmacology; D001327:Autoimmune Diseases / Q000188:drug therapy / Q000235:genetics* / Q000276:immunology; D063385:Cannabinoid Receptor Modulators / Q000276:immunology* / Q000378:metabolism / Q000494:pharmacology; D049109:Cell Proliferation / Q000187:drug effects; D002478:Cells, Cultured; D004252:DNA Mutational Analysis; D015536:Down-Regulation / Q000235:genetics / Q000276:immunology; D063388:Endocannabinoids; D005787:Gene Frequency / Q000235:genetics; D020022:Genetic Predisposition to Disease / Q000235:genetics*; D005989:Glycerides / Q000276:immunology / Q000378:metabolism / Q000494:pharmacology; D005998:Glycine / Q000031:analogs & derivatives / Q000276:immunology / Q000378:metabolism / Q000494:pharmacology; D006720:Homozygote; D006801:Humans; D007155:Immunologic Factors / Q000276:immunology* / Q000378:metabolism / Q000494:pharmacology; D007165:Immunosuppression Therapy / Q000379:methods / Q000639:trends; D008213:Lymphocyte Activation / Q000187:drug effects / Q000276:immunology; D009154:Mutation / Q000235:genetics; D011110:Polymorphism, Genetic / Q000235:genetics*; D043885:Receptor, Cannabinoid, CB2 / Q000819:agonists / Q000037:antagonists & inhibitors / Q000235:genetics*; D013601:T-Lymphocytes / Q000187:drug effects / Q000276:immunology
D001095:Arachidonic Acids; D063385:Cannabinoid Receptor Modulators; D063388:Endocannabinoids; D005989:Glycerides; D007155:Immunologic Factors; C465623:N-arachidonylglycine; D043885:Receptor, Cannabinoid, CB2; C094503:glyceryl 2-arachidonate; D005998:Glycine